Promising Alzheimer’s Treatment Advances: Analyst Recommends Buy for Annovis Bio

Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Annovis Bio (ANVS – Research Report) and keeping the price target at $8.00.

Jason McCarthy has given his Buy rating due to a combination of factors related to Annovis Bio’s promising developments in Alzheimer’s disease treatment. The company is advancing its Phase 3 study of buntanetap, targeting early Alzheimer’s patients, with initial symptomatic data expected by mid-2026. This data could be pivotal for regulatory milestones, potentially supporting a New Drug Application (NDA) submission if results are positive.
Annovis Bio’s prior Phase 2/3 study demonstrated significant efficacy in a subgroup of mild Alzheimer’s patients, with improvements observed across multiple doses of buntanetap. The company’s financial position, with a cash runway extending into the fourth quarter of 2025, supports its ongoing research and development efforts. These factors collectively contribute to McCarthy’s optimistic outlook and Buy rating for Annovis Bio.